AlgaEU
AlgaEurope 2026
4BlueTech
← Back to all tracks
Track #11
4BlueTech
From the first Chlamydomonas nuclear transformation in 1989 to CRISPR base-editing in marine diatoms at single-nucleotide resolution in 2023 — the genetic toolkit for algae has advanced from blunt-force biolistics to precise metabolic rewiring with minimal off-target effects.
| Method | Efficiency | Cell wall required? | Compartment | Best species |
|---|---|---|---|---|
| Biolistics (gene gun) | Medium (10⁻³–10⁻⁵) | No — penetrates wall | Nucleus + Plastid | Chlamydomonas (chloroplast), Haematococcus |
| Electroporation | High (10⁻²–10⁻³) | Wall-free required | Nucleus | Phaeodactylum, Nannochloropsis, Chlamydomonas |
| Agrobacterium | Medium | No — T-DNA bypasses | Nucleus (random) | Chlamydomonas, Chlorella |
| Glass bead vortex | Low (10⁻⁵) | Wall-free required | Nucleus | Chlamydomonas (cell-wall mutants) |
| Lipid nanoparticles | High (10⁻¹–10⁻²) | No | Nucleus | Emerging — demonstrated in Chlorella (2022) |
Efficiency figures are colony-forming transformants per µg DNA input. Electroporation with ribonucleoprotein (RNP) Cas9 delivery (protein + gRNA, no plasmid) currently gives best results for CRISPR in Phaeodactylum and Nannochloropsis — avoiding stable foreign DNA insertion and reducing regulatory burden under EU GMO Directive 2001/18/EC.
| System | Cut type | On-target efficiency | Off-target risk | Best use case |
|---|---|---|---|---|
| Cas9 (SpCas9) | Blunt DSB (both strands) | High (60–90%) | Moderate | Gene knockouts; insertions; high-throughput screens |
| Cas12a (Cpf1) | Staggered DSB (5′ overhang) | High (50–80%) | Low | Multiplexed knockouts (AT-rich PAM preferred) |
| dCas9-CRISPRi | None — steric block | High repression (80–97%) | Minimal | Conditional gene silencing; metabolic flux analysis |
| Base Editor (ABE/CBE) | Single-strand nick only | Very high (>90%) | Very Low | Single-codon changes; point mutation modelling |
| Prime Editing | Nick + reverse transcription | Medium (20–60%) | Lowest known | Complex multi-base insertions; scarless edits |
Data from Jiang & Bhatt (2020), Banerjee et al. (2022, dCas9 in Chlamydomonas), and Xie et al. (2023, base editing in Phaeodactylum). EU GMO Directive interpretation: RNP-delivered CRISPR with no stable integration may fall outside GMO scope — European Court of Justice ruling pending as of October 2026.
Constraint-based reconstruction and analysis (COBRA) metabolic models now cover >15 microalgae species, enabling in-silico identification of flux bottlenecks before experimental CRISPR screens. 4BlueTech's computational pipeline screens 500+ gene targets in Nannochloropsis weekly, ranking by predicted fucoxanthin/EPA impact for wet-lab validation.
The chloroplast genome of Chlamydomonas is directly transformable with ~10-fold higher transgene expression than nuclear integration. New orthogonal ribosomes in the plastid (introduced by Moll & Schuphan, 2022) prevent cross-reactivity with native translation machinery, enabling stable metabolic pathway installation without fitness cost.
Algal cell-free extracts enable rapid (2–4 h) testing of promoter-gene combinations without transformation. Chlamydomonas cell-free systems (pioneered at UC San Diego, 2022) can screen 96-well plates of construct variants in parallel — compressing the design-build-test cycle from weeks to days.
The European Commission's proposed New Genomic Techniques (NGT) regulation (2023) — pending final Council approval — would classify RNP-CRISPR edited algae with no foreign DNA as "NGT1" (equivalent to conventional breeding). This would remove the need for GMO Directive authorization for knockout strains, unlocking commercial deployment for dozens of currently stalled engineered strains.
4BlueTech Molecular Programme
4BlueTech's genetic tools programme focuses exclusively on RNP-delivered CRISPR and dCas9-based transcriptional regulation in Phaeodactylum tricornutum and Nannochloropsis gaditana — the two species most relevant to the CO₂-to-fucoxanthin pipeline. All edits are foreign-DNA-free. A library of 47 validated sgRNAs targeting the fucoxanthin and EPA synthesis pathways is available for collaboration under Material Transfer Agreement. Contact 4bt-science@4bluetech.eu to access.